From: Indian Civil Society Organisations To: Johnson & Johnson -and- the Government of the United States cc: Government of India   17:00, 16th September, 2021     600 million doses of the Johnson & Johnson vaccine currently being made in India cannot go to the European Union or the United States; they must go where they are most needed.       Johnson & Johnson has failed to produce enough of its own vaccine; the United States Government has the power to make them license manufacturers all over the world in order to make billions more doses of their vaccine available. […]

An extensive new report (in Portuguese only, for now) was launched on December 19, 2018 at Fiocruz in Rio. For the full text and data, head over to the other sections on this website. See more here: http://naf.ensp.fiocruz.br/pt-br/livros

On the 19th of December 2018, a new and extensive report analysing the monopoly and patent situation with key drugs procured by the Ministry of Health in Brazil will be launched at Fiocruz in Rio

Between 2 & 3 December, 2018, the accessibsa project held a meeting in Bangalore for civil society activists and access to medicines experts. The meeting, held over two days, was primarily designed to explain the work of the accessibsa project, and connect our work to other work being done in India – as well as evolve a set of collective steps we can take in the future to improve access to medicines in India. The meeting was organised by Vivek Divan and Kajal Bhardwaj.

On September 29, 2018, the accessibsa project presented some findings from our work at the Global IP Congress in Washington DC. Present on the panel: Feroz Ali (IIT Madras/India), Andrew Rens (American University/South Africa), Marcela Vieira (Human Rights Lawyer/ Brazil) and Achal Prabhala (Shuttleworth Fellow), along with discussants, Amy Kapczynski (Yale Law School) and Marumo Nkomo (Department of Trade and Industry, Government of South Africa).   Watch video here: https://www.youtube.com/watch?v=Jmboxh5m5U4&feature=youtu.be 

ABIA, in partnership with the accessibsa project, protested pharma giant Gilead’s pursuit of patents on Sofosbuvir, a critical Hepatitis-C drug in Brazil. ABIA urged the Brazilian government to reject Gilead’s one remaining patent application for Sofosbuvir, a move which would allow the more affordable generic to be legally available in Brazil. For more, see here.     Images and video from demonstrations in Rio de Janeiro and São Paulo:

Join us for the launch of STANDING UP FOR OUR LIVES – A History of the Access to Medicines Movement in South Africa, at the International AIDS Conference in Amsterdam on 24 July. View the pdf at the link below. Standing Up For Our Lives!   You can see Section27’s history of access to medicines in South Africa, with text, audio and video, here: https://standingupforourlives.section27.org.za/

A History of the Access to Medicines Movement in South Africa